All Cancer articles
-
BusinessJ&J now faces talc cancer claims in the UK
Alongside nearly 70,000 US lawsuits, over 3000 claimants have filed joint UK legal action
-
WebinarDeveloping a CITK protein degrader using the QuicTPD™ platform
Join us on 18 November to learn about the latest technology to accelerate the design of cancer treatments
-
BusinessTitanium dioxide loses EU carcinogen label after court ruling
EU products no longer have to carry warnings about cancer risk from inhalation
-
WebinarIon suppression correction and normalisation in metabolomics
Join us on 5 November to learn new ways to improve data consistency with mass spectrometry
-
BusinessSanofi to buy Blueprint Medicines for over $9 billion
Blueprint has one approved drug and enhances Sanofi’s immunology portfolio
-
ResearchNanocomplex becomes a master of shape-shifting to target tumour cells
Switching from nanofibres in the blood to virus-like particles in a tumour environment brings drugs to where they are needed
-
OpinionThe women-led health projects doing things differently
Innovative approaches to awareness and participation
-
BusinessMerck KGaA to buy cancer specialist SpringWorks
$3.9 billion deal boosts Merck’s pipeline as it faces patent expiries
-
BusinessJ&J’s third talc bankruptcy settlement attempt denied
Company says it will return to courts to fight talc cancer claims
-
BusinessBayer ordered to pay more than $2 billion to US cancer victim
Jury decided glyphosate-based Roundup herbicide caused cancer, but company will appeal
-
OpinionGetting into the weeds of the glyphosate debate
Assessments of the risk posed by the controversial herbicide depend on how the evidence is weighed
-
BusinessUS government moves to block J&J talc bankruptcy resolution
Firm’s third attempt to shift claims to a subsidiary had gained significant support
-
FeatureBlood biopsies for cancer
Testing small amounts of blood for the presence of disease markers could revolutionise how we detect cancer. Clare Sansom reports
-
BusinessPan-cancer approval shows huge potential for antibody–drug conjugates
Enhertu gains approval based on gene expression rather than tumour location
-
ResearchAlgorithm designs proteins from scratch that can bind drugs and small molecules
Strategy could stop an overdose or produce an antidote to a poison
-
BusinessBig deals confirm renewed interest in radiopharmaceuticals
Acquisitions of RayzeBio and Point Biopharma highlight the potential of targeting radioactivity directly to tumour cells
-
BusinessIllumina to give up Grail as competition appeals fail
Sequencing giant will sell off its former spin-out in accordance with regulator orders
-
BusinessLife-saving cancer gene therapy under investigation after being linked to rare secondary cancers
US drug agency examining six CAR-T therapies after reports of T-cell malignancies
-
-
BusinessThree US juries side with cancer victims over Bayer on Roundup
Bayer unit Monsanto has lost its ‘winning streak’ of nine defence verdicts, and the company plans to appeal